ReCode Therapeutics Gets New CFF Funding for Gene Editing

ReCode Therapeutics announced new funding from the Cystic Fibrosis Foundation on August 6, 2026, to support a research collaboration with an unnamed gene-editing company. ReCode will contribute its Selective Organ Targeting lipid nanoparticle delivery platform, while the partner will contribute gene-editing technology aimed at correcting mutations in CFTR, the gene that causes cystic fibrosis.

The funding amount and deal structure were not disclosed. That restraint matters because the announcement is best understood as targeted research-program support, not a conventional venture round with a disclosed valuation, lead investor, or ownership stake.

The strategic case is straightforward: gene editing is useful only if the editing machinery reaches the right cells. ReCode is betting that its lung-focused delivery work can solve that problem, while the Foundation is putting more capital behind approaches intended for people who remain underserved by existing CFTR modulators.

What ReCode and the Cystic Fibrosis Foundation Announced

The new collaboration splits the technical work along a logical seam. ReCode will provide its SORT lipid nanoparticle platform, which is designed to direct genetic cargo to selected organs, tissues, and cells beyond the liver. The unnamed collaborator will provide the editing technology, and the companies plan to work jointly toward one or more development candidates, clinical development, and commercialization.

ReCode did not name the partner or describe the editing modality, target mutations, candidate-selection timeline, or economics. Those gaps are material, but they do not erase the immediate signal: the Cystic Fibrosis Foundation is continuing to fund delivery and editing work around ReCode after supporting multiple earlier programs.

The target is CFTR, the cystic fibrosis transmembrane conductance regulator gene. Mutations in CFTR disrupt the production or function of the CFTR protein, contributing to thick mucus and disease across the lungs and other organs. Correcting those mutations at the DNA level could pursue a more durable intervention, but the new collaboration remains at the research stage and has not produced a clinical candidate.

Why Lung Delivery Is the Real Technical Contest

The easiest version of the gene-editing story ends at the editor. The more demanding version begins with delivery because DNA- or RNA-based therapies must travel through mucus, cross cellular barriers, reach the correct airway cells, release useful cargo, and do it with a safety profile that can survive development.

The Cystic Fibrosis Foundation's delivery overview identifies mucus and cell membranes as major barriers to getting genetic therapies into lung cells. It also explains why editing-tool developers and delivery-platform developers need to work together rather than pretending either half of the stack is sufficient alone.

ReCode's SORT platform grew from work led by co-founder Daniel J. Siegwart, Ph.D., at UT Southwestern. The company says the platform adds a distinct lipid component to conventional lipid nanoparticles so distribution can be tuned toward selected organs and cells. In this collaboration, ReCode is not supplying the molecular editor. It is supplying the delivery system that must make the editor biologically relevant.

RCT2100 Gives ReCode a Nearer Clinical Milestone

The gene-editing program is early, but ReCode's cystic fibrosis strategy is not starting from zero. The company is also developing RCT2100, an investigational inhaled CFTR mRNA therapy designed to deliver a correct copy of CFTR mRNA to lung cells so they can make functional CFTR protein.

ReCode said RCT2100 received FDA Fast Track designation on February 24, 2026, and that its Phase 2a study is fully enrolled, ongoing, and expected to produce data in Q4 2026. The Cystic Fibrosis Foundation's trial listing describes the combination study with ivacaftor as closed to enrollment.

RCT2100 and the new editing collaboration pursue different mechanisms. The mRNA program aims to give lung cells temporary working instructions and may require repeat dosing, while gene editing aims to change disease-causing DNA and could seek a more durable result. The Q4 readout will not validate the new editing program, but it can provide a nearer test of ReCode's broader claim that its delivery platform can move genetic cargo into human airways.

Historical Funding Adds Context, Not a Current Price Tag

The Foundation's support for ReCode has accumulated across distinct programs. In January 2023, it agreed to invest up to $15M in ReCode's mRNA program, including an initial $10M equity investment. In November 2024, it committed up to $15M to a gene-editing collaboration between ReCode and Intellia Therapeutics.

In September 2025, ReCode disclosed an additional $3M for the ongoing RCT2100 Phase 2 trial and said the Foundation had agreed to invest up to $33M across its mRNA and gene-editing research programs. That prior total should not be mistaken for the August 2026 commitment because the new announcement does not publish an updated cumulative figure.

The distinction also matters because the Foundation now lists the ReCode and Intellia program as completed, with no active CF development under that collaboration. ReCode's August announcement describes a new, unnamed partner, so attaching Intellia's name to the new work would turn historical context into a factual error.

Heather Clark Takes the CEO Role as ReCode Narrows Its Focus

ReCode paired the funding announcement with a leadership transition. Heather L. Clark, M.S., became CEO effective July 1, 2026, after leading the company's cystic fibrosis franchise, program-management office, Foundation relationship, and RCT2100 program.

Clark previously spent more than 20 years at Vertex Pharmaceuticals, where ReCode says she helped discover and develop five FDA-approved cystic fibrosis therapies and managed Vertex's long-running alliance with the Foundation. That background gives the transition an unusually direct strategic fit: the new CEO has spent much of her career translating cystic fibrosis science, alliance management, and program execution into drug-development decisions.

Shehnaaz Suliman, M.D., MBA, M.Phil., moved from president and CEO to executive chair. The arrangement keeps Suliman involved in strategic and operational guidance while putting day-to-day leadership under an executive already responsible for ReCode's core cystic fibrosis work.

What the Investment Signals for Genetic Medicine

The new funding is a vote for specialization. ReCode brings delivery, the collaborator brings editing, and the Foundation brings disease expertise, capital, research infrastructure, and a patient-centered view of what the program must eventually accomplish.

It is also a reminder that platform companies have to earn their claims one tissue at a time. A lipid nanoparticle system can look broad on a pipeline slide, but the operating proof comes from whether it reaches the right cells, carries the right payload, produces measurable activity, and remains tolerable in people.

ReCode now has two timelines running in parallel. RCT2100 offers a disclosed Q4 2026 clinical milestone, while the gene-editing collaboration must still reveal its partner, editing approach, candidate plan, and preclinical evidence. The capital is useful, but the next layer of credibility will come from those specifics and from data connecting delivery precision to outcomes meaningful for people with cystic fibrosis.